Pharmacodynamics - info-atbvac

info-atbvac > Pharmacodynamics

Suboptimal dosing of fluconazole in critically ill patients. ( Eline W Muilwijk et al. )

Suboptimal dosing of fluconazole in critically ill patients – time to rethink dosing.

22 sept | Dr Jean-Pierre-Bru

Fluconazole is frequently used for treatment of invasive Candida infections in critically ill patients as primary therapy or early “step … Suite

Pulmonary diffusion of dalbavancin could allow its use in the treatment of pneumonia ( Rappo U. et al. )

Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1,500-Milligram Infusion.

26 mar | Dr Olivier Leroy

Pneumonia is frequently caused by gram-positive cocci including S. aureus and S. pneumoniae. Dalbavancin is effective against these pathogens and … Suite

Rapid availability of triazole serum concentration seem crucial and cost effective ( McCreary EK. et al. )

Impact of triazole therapeutic drug monitoring availability and timing.

14 nov | Dr Olivier Leroy

The utility of therapeutic drug monitoring (TDM) is pronounced in drugs with wide interpatient pharmacokinetic variability, a demonstrated relationship between … Suite

Which pharmacodynamics targets for β-lactam in Gram-negative bloodstream infections in the critically ill ? ( G. Wong et al. )

β-Lactam pharmacodynamics in Gram-negative bloodstream infections in the critically ill.

13 nov | Dr Jean-Pierre Bru

The objective was to better determine the β-lactam exposure associated with positive clinical outcomes for Gram-negative blood stream infection (BSI) … Suite